AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17672073 — intervention group
Group type: COMPARATOR
Intervention: Sodium diclofenac (150 mg/day)
Number of subjects: 90
Study 15355143 — intervention group
Group type: EXPERIMENTAL
Intervention: High perceptual load
Number of subjects: 0
Study 15355143 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory load
Number of subjects: 0
Study 15355143 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task coordination load
Number of subjects: 0
Study 15355143 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive control functions available (low cognitive load)
Number of subjects: 0
Study 11226652 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral feeding (EF)
Number of subjects: 22
Study 11226652 — intervention group
Group type: COMPARATOR
Intervention: Delayed enteral feeding (DF)
Number of subjects: 22
Study 9845406 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (250 microg/h)
Number of subjects: 6
Study 9845406 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 6
Study 7584294 — intervention group
Group type: EXPERIMENTAL
Intervention: Korsakoff amnesics
Number of subjects: 0
Study 7584294 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 2318087 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking on an exercise treadmill at 3.2 km/hr
Number of subjects: 10
Study 2318087 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking on an exercise treadmill at 6.4 km/hr
Number of subjects: 10
Study 2318087 — intervention group
Group type: COMPARATOR
Intervention: Standing at rest
Number of subjects: 10
Study 343226 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain acetylsalicylic acid (ASA) tablet
Number of subjects: 8
Study 343226 — intervention group
Group type: EXPERIMENTAL
Intervention: Microencapsulated acetylsalicylic acid (ASA) tablet
Number of subjects: 8
Study 343226 — intervention group
Group type: COMPARATOR
Intervention: Control examinations (before ASA treatment)
Number of subjects: 8
Study 343226 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between plain ASA and microencapsulated ASA
Number of subjects: 8
Study 343226 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA concentration in plasma
Number of subjects: 8
Study 31351105 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU)
Number of subjects: 100
Study 31351105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 28605879 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban alone
Number of subjects: 287
Study 28605879 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (Enoxaparin) alone
Number of subjects: 287
Study 28605879 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (Enoxaparin followed by Rivaroxaban)
Number of subjects: 287
Study 24958738 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 0
Study 24958738 — intervention group
Group type: COMPARATOR
Intervention: HDL isolated from CHF patients (HDLNYHA)
Number of subjects: 0
Study 24958738 — intervention group
Group type: COMPARATOR
Intervention: HDL isolated from healthy subjects (HDLHealthy)
Number of subjects: 0
Study 23470649 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 2 g/kg total dose (400 mg/kg per day for 5 days)
Number of subjects: 78
Study 23470649 — intervention group
Group type: COMPARATOR
Intervention: Anti-D immunoglobulin 50 μg/kg
Number of subjects: 78
Study 23470649 — intervention group
Group type: COMPARATOR
Intervention: Anti-D immunoglobulin 75 μg/kg
Number of subjects: 78
Study 21612757 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% ethanol lock (EL)
Number of subjects: 30
Study 21612757 — intervention group
Group type: COMPARATOR
Intervention: Standard locks (SL)
Number of subjects: 30
Study 19640511 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 789
Study 19640511 — intervention group
Group type: COMPARATOR
Intervention: Perphenazine
Number of subjects: 789
Study 19640511 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 789
Study 19640511 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 789
Study 19640511 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 789
Study 16685289 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilized stannous fluoride + sodium hexametaphosphate dentifrice (Crest Pro‐Health)
Number of subjects: 90
Study 16685289 — intervention group
Group type: COMPARATOR
Intervention: Sodium fluoride control dentifrice
Number of subjects: 90
Study 17007484 — intervention group
Group type: EXPERIMENTAL
Intervention: Seamless probation
Number of subjects: 272
Study 17007484 — intervention group
Group type: COMPARATOR
Intervention: Traditional probation
Number of subjects: 272
Study 14572428 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention group (first year)
Number of subjects: 550
Study 14572428 — intervention group
Group type: COMPARATOR
Intervention: Control group (second year)
Number of subjects: 550
Study 10211920 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg daily plus pindolol 7.5 mg daily
Number of subjects: 31
Study 10211920 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg daily plus mianserin 30 mg daily
Number of subjects: 31
Study 10211920 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 20 mg daily
Number of subjects: 31
Study 8699500 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight-week peer counseling and leadership training group
Number of subjects: 204
Study 8699500 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 204
Study 1860197 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg preoperatively
Number of subjects: 351
Study 1860197 — intervention group
Group type: COMPARATOR
Intervention: Placebo preoperatively
Number of subjects: 351
Study 7046498 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (0.1 mg/kg) preceded by diazepam (0.1 mg/kg)
Number of subjects: 4
Study 7046498 — intervention group
Group type: COMPARATOR
Intervention: Etomidate
Number of subjects: 4
Study 7046498 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate preceded by pentazocine
Number of subjects: 4
Study 7046498 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate preceded by diazepam
Number of subjects: 4
Study 31976633 — intervention group
Group type: EXPERIMENTAL
Intervention: HAPA-intervention (sedentary behaviour)
Number of subjects: 96
Study 31976633 — intervention group
Group type: COMPARATOR
Intervention: HAPA-attention control (physical activity)
Number of subjects: 96
Study 31976633 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 96
Study 28682124 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiomat® training
Number of subjects: 99
Study 28682124 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-specific, low-intensity exercises)
Number of subjects: 99
Study 29104320 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone adherence condition (N = 35)
Number of subjects: 67
Study 29104320 — intervention group
Group type: COMPARATOR
Intervention: Independent of naltrexone adherence condition (N = 32)
Number of subjects: 67
Study 26365337 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide
Number of subjects: 63
Study 26365337 — intervention group
Group type: COMPARATOR
Intervention: NPH
Number of subjects: 63
Study 24064695 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (1200 mg daily) plus placebo
Number of subjects: 159
Study 24064695 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (100 μg) plus placebo
Number of subjects: 159
Study 24064695 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 and calcium
Number of subjects: 159
Study 24064695 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 159
Study 21958551 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention
Number of subjects: 283
Study 19133045 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine exteriorisation
Number of subjects: 210
Study 19133045 — intervention group
Group type: COMPARATOR
Intervention: Non-exteriorisation
Number of subjects: 210
Study 16786040 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant androgen deprivation (NAD) for < or =6 months
Number of subjects: 560
Study 16786040 — intervention group
Group type: COMPARATOR
Intervention: No neoadjuvant androgen deprivation (NAD)
Number of subjects: 560
Study 12767658 — intervention group
Group type: EXPERIMENTAL
Intervention: Juice Plus (JP) and Vineyard (V) combination
Number of subjects: 38
Study 12767658 — intervention group
Group type: EXPERIMENTAL
Intervention: Juice Plus (JP) alone
Number of subjects: 38
Study 12767658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 12767658 — intervention group
Group type: EXPERIMENTAL
Intervention: Juice Plus (JP) and Vineyard (V) combination and JP alone
Number of subjects: 38
Study 10694785 — intervention group
Group type: COMPARATOR
Intervention: Low flavonoid diet
Number of subjects: 10
Study 10694785 — intervention group
Group type: EXPERIMENTAL
Intervention: High flavonols diet (77.3 mg/day or 110.4 mg/day)
Number of subjects: 10
Study 9333109 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (30 microg/min)
Number of subjects: 8
Study 9333109 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin II (4 to 64 ng/min)
Number of subjects: 8
Study 9333109 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine (1 to 128 ng/min)
Number of subjects: 8
Study 9333109 — intervention group
Group type: COMPARATOR
Intervention: Single deep breath
Number of subjects: 8
Study 8218961 — intervention group
Group type: EXPERIMENTAL
Intervention: Celaskon 60 mg (CK60)
Number of subjects: 9
Study 8218961 — intervention group
Group type: EXPERIMENTAL
Intervention: Celaskon 500 mg (CK500)
Number of subjects: 9
Study 8218961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 3081991 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 10
Study 3081991 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine with ethanol
Number of subjects: 10
Study 28903787 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive methods combined with habit reversal therapy (MCT/HRT)
Number of subjects: 34
Study 28903787 — intervention group
Group type: COMPARATOR
Intervention: Waiting list group
Number of subjects: 34
Study 26859092 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve strain Yakult (BBG‐01)
Number of subjects: 0
Study 24211870 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomographic EEG neurofeedback (NF)
Number of subjects: 25
Study 24211870 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback (EMG-BF)
Number of subjects: 25
Study 23364913 — intervention group
Group type: EXPERIMENTAL
Intervention: Average-of-two walk distances after lung volume reduction surgery
Number of subjects: 396
Study 23364913 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-of-two walk distances after lung volume reduction surgery
Number of subjects: 396
Study 23364913 — intervention group
Group type: EXPERIMENTAL
Intervention: Average-of-two walk distances
Number of subjects: 396
Study 23364913 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-of-two walk distances
Number of subjects: 396
Study 20859151 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-microgram estradiol vaginal tablets for 52 weeks
Number of subjects: 541
Study 18797054 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional verapamil
Number of subjects: 54
Study 18797054 — intervention group
Group type: COMPARATOR
Intervention: Intralesional triamcinolone
Number of subjects: 54
Study 15816634 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary administration of standardized mistletoe extract (Iscador)
Number of subjects: 0
Study 14676074 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (up to 37.5 mg)
Number of subjects: 36
Study 14676074 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (up to 300 mg)
Number of subjects: 36
Study 14676074 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (up to 500 mg)
Number of subjects: 36
Study 14676074 — intervention group
Group type: COMPARATOR
Intervention: Naproxen sodium (500 mg)
Number of subjects: 36
Study 14676074 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 36
Study 14676074 — intervention group
Group type: COMPARATOR
Intervention: Aspirin-sensitive patients
Number of subjects: 36
Study 14676074 — intervention group
Group type: COMPARATOR
Intervention: Aspirin-induced urticaria
Number of subjects: 36
Study 10822094 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention training for primary care physicians and nurses
Number of subjects: 11000
Study 10822094 — intervention group
Group type: EXPERIMENTAL
Intervention: Community primary care practices implementing the intervention
Number of subjects: 11000
Study 8896479 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasculour II Albumin pre‐impregnated prosthesis (VA group)
Number of subjects: 65
Study 8896479 — intervention group
Group type: COMPARATOR
Intervention: Preclotted Vasculour II prosthesis (V group)
Number of subjects: 65
Study 1863024 — intervention group
Group type: EXPERIMENTAL
Intervention: pH‐sensitive, polymer‐coated oral preparation of mesalamine 2.4 g/d
Number of subjects: 158
Study 1863024 — intervention group
Group type: EXPERIMENTAL
Intervention: pH‐sensitive, polymer‐coated oral preparation of mesalamine 1.6 g/d
Number of subjects: 158
Study 1863024 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 158
Study 6600417 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated coronary artery bypass grafting (CABG)
Number of subjects: 1086
Study 6600417 — intervention group
Group type: COMPARATOR
Intervention: Patients younger than 65 years (control group)
Number of subjects: 1086
Study 6600417 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged 65-69 years
Number of subjects: 1086
Study 6600417 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged 70-74 years
Number of subjects: 1086
Study 6600417 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged 75 years or older
Number of subjects: 1086
Study 6600417 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged 65 years or older
Number of subjects: 1086
Study 6600417 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary arteriography
Number of subjects: 1086
Study 6600417 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass surgery
Number of subjects: 1086
Study 30768413 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with depression and suicidal ideation (n=22)
Number of subjects: 139
Study 30768413 — intervention group
Group type: COMPARATOR
Intervention: Children with depression without suicidal ideation (n=57)
Number of subjects: 139
Study 30768413 — intervention group
Group type: COMPARATOR
Intervention: Healthy children (n=60)
Number of subjects: 139
Study 30768413 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with depression and SI
Number of subjects: 139
Study 30768413 — intervention group
Group type: EXPERIMENTAL
Intervention: Older children
Number of subjects: 139
Study 30768413 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with more television use
Number of subjects: 139
Study 29332628 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard risk factors (smoking)
Number of subjects: 570
Study 29332628 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial factors (exhaustion, anger, anxiety, depression)
Number of subjects: 570
Study 29332628 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological and social risk factors
Number of subjects: 570
Study 27170028 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic data capture
Number of subjects: 261
Study 27170028 — intervention group
Group type: COMPARATOR
Intervention: Handwritten data capture
Number of subjects: 261
Study 25259747 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime administration of antihypertensive drugs
Number of subjects: 41
Study 22959763 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-hydroxyprogesterone caproate (17-OHPC)
Number of subjects: 217
Study 22959763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study 22959763 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing hormone
Number of subjects: 217
Study 19665364 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 6 mg (group E)
Number of subjects: 60
Study 19665364 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine 100 microg (group P)
Number of subjects: 60
Study 19665364 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 18612059 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (best practice interventions with practice enhancement assistant)
Number of subjects: 16
Study 18612059 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 16
Study 16079222 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal glucose infusion (3 kcal/min) with guar gum (4 g)
Number of subjects: 8
Study 16079222 — intervention group
Group type: COMPARATOR
Intervention: Intraduodenal glucose infusion (3 kcal/min)
Number of subjects: 8
Study 12417824 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management training (8 sessions over 10 weeks)
Number of subjects: 33
Study 12417824 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed control group
Number of subjects: 33
Study 10977378 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored weight loss materials
Number of subjects: 198
Study 10977378 — intervention group
Group type: COMPARATOR
Intervention: Non-tailored weight loss materials (good fit)
Number of subjects: 198
Study 10977378 — intervention group
Group type: COMPARATOR
Intervention: Non-tailored weight loss materials (moderate fit)
Number of subjects: 198
Study 10977378 — intervention group
Group type: COMPARATOR
Intervention: Non-tailored weight loss materials (poor fit)
Number of subjects: 198
Study 8803650 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg daily)
Number of subjects: 357
Study 8803650 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20 mg daily)
Number of subjects: 357
Study 1321037 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (LD 2 mg kg‐1 and MD 6 mg kg‐1 h‐1)
Number of subjects: 75
Study 1321037 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (LD 0.3 mg kg‐1 and MD 0.6 mg kg‐1 h‐1)
Number of subjects: 75
Study 1321037 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (LD 0.2 mg kg‐1 and MD 0.120 mg kg‐1 h‐1)
Number of subjects: 75
Study 1321037 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexitone (LD 1.5 mg kg‐1 and MD 4 mg kg‐1 h‐1)
Number of subjects: 75
Study 1321037 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydrobenzperidol (0.05-0.23 mg kg‐1) and alfentanil (LD 0.100 mg kg‐1 and MD 0.060 mg kg‐1 h‐1)
Number of subjects: 75
Study 6547878 — intervention group
Group type: EXPERIMENTAL
Intervention: pindolol, 15 mg daily
Number of subjects: 25
Study 6547878 — intervention group
Group type: COMPARATOR
Intervention: hydrochlorothiazide, 50 mg daily
Number of subjects: 25
Study 6547878 — intervention group
Group type: EXPERIMENTAL
Intervention: both drugs combined
Number of subjects: 25
Study 30989456 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% multi-strain probiotic
Number of subjects: 180
Study 30989456 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% multi-strain probiotic
Number of subjects: 180
Study 30989456 — intervention group
Group type: COMPARATOR
Intervention: 0% multi-strain probiotic (Control, T0)
Number of subjects: 180
Study 28902118 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load group (LLG)
Number of subjects: 32
Study 28902118 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-load group (MLG)
Number of subjects: 32
Study 28902118 — intervention group
Group type: EXPERIMENTAL
Intervention: High-load group (HLG)
Number of subjects: 32
Study 28902118 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 32
Study 26628328 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Bifidobacterium breve BBG-001 (8.2 to 9.2 log10 CFU)
Number of subjects: 1315
Study 26628328 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dilute infant formula)
Number of subjects: 1315
Study 25354407 — intervention group
Group type: EXPERIMENTAL
Intervention: Podiatric treatment
Number of subjects: 205
Study 25354407 — intervention group
Group type: COMPARATOR
Intervention: Standardized shoe advice
Number of subjects: 205
Study 22177550 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 192
Study 22177550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 20810805 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed net use
Number of subjects: 553
Study 20810805 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor residual spraying with carbamate or organophosphate insecticide
Number of subjects: 553
Study 20810805 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 553
Study 18991037 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% monotherapy for 12 weeks
Number of subjects: 53
Study 18991037 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Latanoprost 0.005% and Nipradilol 0.25% after 12 weeks
Number of subjects: 53
Study 18991037 — intervention group
Group type: EXPERIMENTAL
Intervention: Nipradilol 0.25% monotherapy for 12 weeks
Number of subjects: 53
Study 18991037 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Nipradilol 0.25% and Latanoprost 0.005% after 12 weeks
Number of subjects: 53
Study 16105428 — intervention group
Group type: EXPERIMENTAL
Intervention: ETS+LR
Number of subjects: 20
Study 16105428 — intervention group
Group type: COMPARATOR
Intervention: ETS‐LR
Number of subjects: 20
Study 11815321 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotin supplementation (300 microg/d for 14 days)
Number of subjects: 26
Study 11815321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 12017304 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative adjuvant chemotherapy including mitomycin, anthracyclines, cyclophosphamide, alkylating agents, and 5-fluorouracil
Number of subjects: 0